TG Therapeutics Inc (TGTX)
Cash ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 179,894 | 92,933 | 102,304 | 298,887 | 553,439 |
| Short-term investments | US$ in thousands | 131,106 | 124,575 | 59,374 | 15,876 | 51,987 |
| Total current liabilities | US$ in thousands | 90,679 | 53,720 | 53,201 | 65,384 | 87,554 |
| Cash ratio | 3.43 | 4.05 | 3.04 | 4.81 | 6.91 |
December 31, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($179,894K
+ $131,106K)
÷ $90,679K
= 3.43
The cash ratio of TG Therapeutics Inc has been fluctuating over the years. In December 31, 2020, the cash ratio was 6.91, indicating the company had a comfortable level of cash to cover its current liabilities. However, by December 31, 2022, the cash ratio decreased to 3.04, which could be a cause for concern as it indicates a lower ability to meet short-term obligations with cash alone.
In the following years, there were some improvements in the cash ratio, such as reaching 4.05 by December 31, 2023, and 3.43 by December 31, 2024. While these numbers show some recovery, the cash ratio still remains below the initial level in 2020.
Overall, the trend in the cash ratio suggests that TG Therapeutics Inc may have experienced some challenges in managing its liquidity position over the years, and it would be important for the company to continue monitoring and improving its ability to cover short-term obligations with available cash resources.
Peer comparison
Dec 31, 2024